[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Amazentis SA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":119},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,71,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632761","anti-aging-efficacy-study-on-one-cosmetic-product-containing-mitopure-100632761",false,"NCT07517887","Anti-aging Efficacy Study on One Cosmetic Product Containing Mitopure","Anti-aging Efficacy Study on One Cosmetic Product vs Untreated","HCP-S1","INCLUSION CRITERIA\n\n* Written Informed Consent to participate in the study\n* Written Informed Consent for the use of the images for marketing purposes applies to subgroup participants of study 26.0112.\n* Willingness to actively participate in the study and to come to the scheduled visits\n* Female\n* Male, approximately 10 to 15% with little facial hair\n* From 45 to 65 years of age\n* Healthy skin in the test areas\n* Visible wrinkles in the face (grade 3 to 6 according to proderm wrinkle score)\n\nExclusion criteria\n\n* Female participants: Pregnancy or lactation\n* Drug addicts, alcoholics\n* AIDS, HIV-positive or infectious hepatitis\n* Conditions which exclude a participation or might influence the test reaction\u002Fevaluation\n* Participation or being in the waiting period after participation in cosmetic and\u002For pharmaceutical studies pertaining to the test area\n* Active skin disease at the test area\n* Documented allergies to face\u002Feye care products or their ingredients\n* Diabetes mellitus\n* Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and\u002For hormonal treatment within the last 2 years\n* One of the following illnesses with reduced physical capability\u002Ffitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension (if not adjusted with medication), cardiovascular diseases\n* Epilepsy\n* Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, freckles, etc. at the test area that could influence the investigation\n* Regular use of tanning beds within the last 6 weeks prior to the start of the study\n* Any topical medication at the test area within the last 3 days prior to the start of the study\n* Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and\u002For antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study and throughout the entire course of the study that in the opinion of the investigator may affect the outcome of the study\n* Therapy with antibiotics within the last 2 weeks prior to the start of the study and throughout the entire course of the study that in the opinion of the investigator may affect the outcome of the study\n* Cosmetic surgery procedure in the test area (e.g. laser, facelift) within the last 2 years and throughout the entire course of the study\n* Cosmetic surgery treatments in the test area, e.g. IPL (Intensed Pulsed Light), botox, chemical peel, dermabrasion within the last 2 years prior to the start of the study and throughout the entire course of the study\n* Medical treatment for wrinkle reduction (e.g. peeling with vitamin A or fruit acids) on the face within the last 2 weeks prior to the start of the study and throughout the entire course of the study",true,"ALL","45 Years","65 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim of this study is to investigate the impact of a topical product on skin health and aging",[29,30],"Aging","Wrinkle Appearance","RECRUITING","2026-04-24",{"date":34,"type":35},"2026-04-29","ACTUAL",{"date":37,"type":35},"2026-04-22",{"date":39,"type":23},"2026-10-15",{"name":41,"class":42},"Amazentis SA","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100632763","cerebrospinal-fluid-kinetics-of-urolithin-a-100632763","NCT07517913","Cerebrospinal Fluid Kinetics of Urolithin A","Cerebrospinal Fluid Kinetics of Urolithin A in Humans","neURO","Inclusion Criteria:\n\n* 1\\. Healthy male and female participants aged between 18 and 45 years (both inclusive);\n* 2\\. Non-smoker subject or smoker of not more than 5 cigarettes a day;\n* 3\\. Body Mass Index (BMI) between 18.50-30.00 kg\u002Fm2 inclusive;\n* 4\\. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests), individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator;\n* 5\\. Normal electrocardiogram (ECG) recording on a 12-lead ECG and\u002For chest X-ray (PA view) significant at the screening visit or considered not clinically significant (NCS) by investigators;\n* 6\\. A negative alcohol breath test result at housing;\n* 7\\. Trial participant able to communicate effectively, provide voluntary written informed consent and available for the entire study duration;\n* 8\\. Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee;\n* 9\\. Ability to fast for at least 14.00 hours and consume standard meals;\n* 10\\. Accept to refrain consuming certain foods and supplements at least two weeks before inclusion;\n* 11\\. Female participants must have a negative urine pregnancy test prior to housing;\n* 12\\. Trial participants that can provide adequate evidence of their identity;\n* 13\\. The participants agree to refrain from consuming dietary supplements that could potentially impact either muscle or mitochondrial function or contain Urolithin A, such as resveratrol, pomegranate and ellagitannins, nicotinamide riboside, whey protein, leucine, iso-leucine, l-carnitine, creatinine, coenzyme Q10, vitamin A, niacin, folic acids, vitamin C, vitamin E and probiotic foods and supplements, during the 2 weeks before inclusion and throughout the study;\n* 14\\. Females of childbearing potential agree to use appropriate contraceptive measures like non-hormonal intrauterine devices, barrier methods, and spermicidal agents during the study and 07 days after completion of the study;\n* 15\\. Male agreeing to use appropriate contraceptive measures like the Double Barrier method (Condom), and should not donate sperm, etc. during the study and 07 days after completion of the study.\n\nExclusion Criteria:\n\n* 1\\. Known hypersensitivity to Urolithin A or related product or any component of intervention, presence or history of drug hypersensitivity, allergic disease or lactose intolerance;\n* 2\\. Any history or presence of clinically significant medical condition, such as, but not limited to, cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease, thyroid disease, adrenal dysfunction, or organic intracranial lesion;\n* 3\\. Any treatment which could bring about induction or inhibition of the hepatic microsomal enzyme system within one month of starting the study;\n* 4\\. History or presence of alcoholism or drug abuse;\n* 5\\. History or presence of gastric and\u002For duodenal ulceration;\n* 6\\. History or presence of cancer;\n* 7\\. Difficulty with donating blood;\n* 8\\. Use of any prescribed medication (including herbal remedies) during the two weeks before the start of the study or OTC medicinal products (including herbal remedies) during the week before study initiation and throughout the study;\n* 9\\. Use of medications such as benzodiazepines, anticonvulsants, or barbiturates for one month before the start of the study and throughout the study;\n* 10\\. Trial participant consumed tobacco\u002Ftobacco-containing products, pan or pan masala, gutkha, and masala (containing beetle nut and tobacco) for at least 48.00 hours before initiation of the study and throughout the study;\n* 11\\. Trial participant consumed caffeine and\u002For xanthine-containing foods or beverages (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and grapefruit juice and poppy-containing foods for at least 48.00 hours before initiation of the study and throughout the study;\n* 12\\. Major illness during the 90 days before screening;\n* 13\\. Participation in a drug research study within 90 days of screening;\n* 14\\. Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C, and VDRL;\n* 15\\. History or presence of easy bruising or bleeding;\n* 16\\. Abnormal diet pattern for whatever reason (e.g., low sodium, fasting, and high protein diets) during the four weeks preceding the study;\n* 17\\. Females of childbearing potential with any one of the following reported and documented on the medical history:i. Postmenopausal with spontaneous amenorrhea for at least one year, orii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, oriii. Total hysterectomy and an absence of bleeding for at least 3 months;iv. Female volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 07 days before dosing;\n* 18\\. Pregnant women and nursing mothers;\n* 19\\. Male and females of childbearing potential unwilling to employ appropriate and reliable method of contraception like non-hormonal intrauterine devices, barrier methods, and spermicidal agents, Double Barrier method (Condom) during the study till 07 days after the completion of the study;\n* 20\\. Male volunteers willing to donate sperm during the study till 07 days after the completion of the study.\n* 21\\. Allergy to peanuts, nuts, pea, or gum guar.","18 Years",{"count":54,"type":23},40,[26],"The purpose of this study is to determine the impact of Mitopure® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).",[58],"Healthy Adult",[60,61],"Mitopure","Urolithin A","NOT_YET_RECRUITING","2026-04-08",{"date":65,"type":35},"2026-04-13",{"date":67,"type":23},"2026-05-01",{"date":69,"type":23},"2027-04-01",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":20,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100610761","the-effect-of-urolithin-a-mitopure-supplementation-on-muscle-strength-in-healthy-middle-aged-adults-100610761","NCT07231783","The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults","A Confirmatory, Randomised, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Effects of a Dietary Supplement Containing Urolithin A (Mitopure®) on Muscle Strength and Performance in Healthy Middle-Aged Adults","ATLAS 2","Inclusion Criteria:\n\n* 1\\. Be able to give written informed consent.\n* 2\\. Be between 40 to 65 years of age, inclusive.\n* 3\\. Has a BMI between 25.0 and 34.9 kg\u002Fm2.\n* 4\\. Low physical activity levels as assessed by the International Physical Activity Questionnaire (IPAQ).\n* 5\\. Participants with low VO2 peak (defined as \\\u003C35 mL\u002Fkg\u002Fmin via the ergometer prior to baseline).\n* 6\\. Willing to avoid exercising 48-h prior to study visits and maintain low physical activity status for the duration of the study.\n* 7\\. Willing to avoid caffeine and other stimulants (e.g., energy drinks) 12-h before exercise as per study guidelines.\n* 8\\. Willing to consume the Study Product daily for the duration of the study.\n\nExclusion Criteria:\n\n* 1\\. Participants who are pregnant or wish to become pregnant during the study or who are lactating and\u002For currently breastfeeding.\n* 2\\. Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:\n\n  * a. Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).\n  * b. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that Participant.\n  * c. Sexual partner(s) is\u002Fare exclusively female.\n  * d. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.\n  * e. Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.\n* 3\\. Participants with history of drug and\u002For alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (\\>11 units for women; \\>17 units for men); alcohol\u002Fsubstance abuse disorder).\n* 4\\. Participants consuming large quantities of pomegranate juice or walnuts or frequent consumers of raspberries, strawberries or cloudberries (2-week washout).\n* 5\\. Chronic nicotine use.\n* 6\\. Participants who are unable to swallow capsules.\n* 7\\. Is hypersensitive to or has dietary restrictions for any of the components of the Study Product e.g., gelatine\n* 8\\. Unstable body weight or recent participation in a weight loss program (within 12-weeks prior to screening).\n* 9\\. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:\n\n  * a. Major illness\u002Fsurgery in the 12-weeks prior to screening\n  * b. Diagnosed cardiovascular disease (NHYA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmia, uncontrolled hypertension)\n  * c. Diagnosed liver disease (cirrhosis, end stage liver disease)\n  * d. Diagnosed kidney disease (stage 3b or 4 chronic kidney disease, or kidney failure)\n  * e. Diagnosed gastrointestinal disease (IBS\u002FIBD, diarrhoea, Acid Reflux)\n  * f. Uncontrolled thyroid conditions\n  * g. Uncontrolled diabetes\n  * h. Metallic implants\n  * i. Conditions requiring chemotherapy or immunotherapy.\n* 10\\. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:\n\n  * a. Statins or other medications known to impair mitochondrial function.\n  * b. Anxiolytics, antidepressants, sedative hypnotics (in the 8 weeks prior to visit 1)\n  * c. Antipsychotics, monoamine Oxidase Inhibitors (in the 8 weeks prior to visit 1)\n  * d. Oral anti- infective (antibiotics, antivirals, antifungals) for acute infections (in the 12-weeks prior to visit 1)\n  * e. Proton pump inhibitors (PPIs) (in the 4 weeks prior to visit 1)\n  * f. Corticosteroids (\\> 5mg per day in the past 4 weeks prior to visit 1)\n  * g. GLP-1 agonists (in the 8 weeks prior to visit 1)\n* 11\\. Current or recent (in the past 6-weeks prior to Visit 1) use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited supplements include:\n\n  * a. Mitopure® containing supplements\n  * b. Supplements for muscle strengthening\u002Fbuilding or mitochondrial boosting supplements (e.g. high protein, Vitamin B3 \\[and precursors\\], L-carnitine, CoQ10, NAD+, resveratrol)\n* 12\\. Blood donation in the 8-weeks prior to screening.\n* 13\\. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n* 14\\. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study (physical or muscle performance), the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.","40 Years",{"count":81,"type":23},120,[26],"This is a randomised, double-blind, placebo-controlled, parallel study to assess the effects of Urolithin A (Mitopure®) supplementation on muscle strength and performance in healthy middle-aged adults. Participants will be randomized to consume Mitopure® (500 mg), Mitopure® (1000 mg), or placebo once daily for 6 months.",[85,86],"Healthy Aging","Muscle Function",[61],"2026-03-30",{"date":90,"type":35},"2026-03-31",{"date":92,"type":35},"2025-12-10",{"date":94,"type":23},"2027-10-31",{"name":41,"class":42},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":43},"100438157","the-mitopure-challenge-to-detect-levels-of-urolithin-a-in-dried-blood-spots-100438157","NCT04985630","The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots","Open-labelled Study to Validate Home-based Use of a Health and Wellness Kit (The Mitopure Challenge) to Detect Levels of Urolithin A in Dried Blood Spots After Intake of Mitopure (Proprietary Urolithin A)","Inclusion Criteria:\n\n1. Males and females 18 to 80 years of age;\n2. Is in general good health, as determined by the research team;\n3. Willingness to consume the investigation product, complete questionnaires and to complete the study;\n4. Have given voluntary, electronic, informed consent to be a participant in the study.\n\nExclusion Criteria:\n\n1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial;\n2. Volunteers who plan to donate blood during the study or within 30 days of completing the study;\n3. Subject has a known allergy to the test material's active or inactive ingredients;\n4. Subjects with unstable medical conditions;\n5. Participation in a clinical research trial within 30 days prior to randomization;\n6. Allergy or sensitivity to study ingredients;\n7. Individuals who are cognitively impaired and\u002For who are unable to give informed consent;\n8. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject;\n9. Has taken antibiotics within the previous 30 days.","80 Years",{"count":105,"type":23},250,[26],"Open labelled, virtual home based study to assess the test repeatability and the failure\u002Frejection rate of the samples collected at home by participants.",[85,109,110],"Healthy","Healthy Diet","2025-09-02",{"date":113,"type":35},"2025-09-08",{"date":115,"type":35},"2021-08-30",{"date":117,"type":23},"2026-08-31",{"name":41,"class":42},""]